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Knockdown of brain-derived neurotrophic factor in
specific brain sites precipitates behaviors associated
with depression and reduces neurogenesis
D Taliaz, N Stall, DE Dar and A Zangen
Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel
Depression has been associated with reduced expression of brain-derived neurotrophic factor
(BDNF) in the hippocampus. In addition, animal studies suggest an association between
reduced hippocampal neurogenesis and depressive-like behavior. These associations were
predominantly established based on responses to antidepressant drugs and alterations in
BDNF levels and neurogenesis in depressive patients or animal models for depressive
behavior. Nevertheless, there is no direct evidence that the actual reduction of the BDNF
protein in specific brain sites can induce depressive-like behaviors or affect neurogenesis
in vivo. Using BDNF knockdown by RNA interference and lentiviral vectors injected into
specific subregions of the hippocampus we show that a reduction in BDNF expression in the
dentate gyrus, but not the CA3, reduces neurogenesis and affects behaviors associated with
depression. Moreover, we show that BDNF has a critical function in neuronal differentiation,
but not proliferation in vivo. Finally, we found that a specific BDNF knockdown in the ventral
subiculum induces anhedonic-like behavior. These findings provide substantial support for
the neurotrophic hypothesis of depression and specify anatomical and neurochemical targets
for potential antidepressant interventions. Moreover, the specific effect of BDNF reduction on
neuronal differentiation has broader implications for the study of neurodevelopment and
neurodegenerative diseases.
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Introduction
Several studies have suggested that brain-derived
neurotrophic factor (BDNF)
1–4 and neurogenesis
5–8
have an important function in the pathophysiology
of depression, or at least in the mechanism of
antidepressant action.
1,5,9,10 Postmortem analyses
have reported decreased hippocampal levels of BDNF
in suicide victims
2,4 and depressed individuals.
11 In
addition, a large volume of evidence derived from
animal studies indicates that chronic stress, impli-
cated as a risk factor for depression,
12,13 can decrease
the expression of BDNF in the hippocampus,
14
whereas other studies did not observe such effect.
15
In addition, electroconvulsive seizures
1,16 and admin-
istration of antidepressant drugs can increase hippo-
campal BDNF levels.
1 Moreover, infusion of BDNF
into rat hippocampus results in antidepressant-like
effects, as observed in the forced swim test (FST) and
learned helplessness paradigms.
3 In addition, a recent
study by Adachi et al.
10 showed that hippocampal
BDNF is necessary for the action of antidepressant
drugs in mice, but failed to show an effect of BDNF
reduction on the behavior of untreated mice. Finally,
a general reduction of BDNF expression within the
forebrain of female (but not male) mice induced an
increase in immobility in the FST.
9 There is also
accumulating evidence that hippocampal neurogen-
esis is decreased by stress
8,17–19 and increased by
antidepressant treatment.
6–8 Furthermore, Santarelli
et al.
5 showed that hippocampal neurogenesis is
required for the behavioral effects of current anti-
depressants in the novelty-suppressed feeding para-
digm in mice, but that reduced neurogenesis per se
does not alter the mice latency to feed at the novelty-
suppressed feeding. Some of these observations
provide the basis for the neurotrophic hypothesis of
depression which associates decreased BDNF expres-
sion with depression and increased BDNF expression
with antidepressant action,
20 effects possibly
mediated by alterations in neurogenesis.
7
Despite the substantial amount of data indicating
an association between decreased hippocampal
BDNF levels and depression, and the critical function
of BDNF in antidepressant action, there is no direct
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levels can actually affect behaviors associated with
depression, or perhaps reduced BDNF levels is
merely a side effect of stress and depression. It also
remains unknown whether BDNF expression in
specific hippocampal subregions is more critical than
in other subregions. Moreover, while intrahippocam-
pal BDNF infusion facilitates neurogenesis,
21 there is
no direct evidence that a local reduction in the BDNF
protein actually impairs adult hippocampal neuro-
genesis in vivo. To examine these issues, we sought to
reduce BDNF levels in specific hippocampal sub-
regions, and measure the consequential effects on
behavior and neurogenesis. Reducing BDNF levels by
producing conventional BDNF homozygous ( / )
knockout mice is not practical for this purpose,
because such mice do not survive to adulthood
22
and the use of BDNF heterozygous (þ/ ) mice have
previously resulted in conflicting findings.
23–25 More-
over, this approach does not allow for site-specific
reduction in BDNF. Finally, as BDNF is reduced early
in development in these transgenic mice, it is
unknown what potential compensatory mechanisms
can occur during neurodevelopment. We therefore
made use of RNA interference (see Supplementary
Appendix 1) to allow for BDNF knockdown in
specific regions without interfering with normal
embryonic neurodevelopment. To induce a stable
knockdown, we generated lentiviral vector (LV)
constructs
26,27 expressing short hairpin RNAs
(shRNAs) complementary to the coding exon of the
rat BDNF gene, common to all isoforms of this gene.
28
Lentiviruses allow for long-term expression of these
BDNF shRNAs (shBDNF), as they are capable of
infecting non-dividing cells, and because the genes
they transduce are integrated into the genome of the
target hippocampal cells.
29 This approach was uti-
lized in this study to evaluate whether BDNF knock-
down in specific hippocampal subregions can
actually affect behaviors associated with depression
and whether such a localized reduction in the BDNF
protein can affect neurogenesis in vivo.
Materials and methods
In vitro
Design of shRNAs. Four shRNA sequences, each
complementary to a unique segment of mRNA
transcribed from the coding sequence common to all
isoforms of the rat BDNF gene, were produced.
28 One
scrambled shRNA sequence was designed as a control
(shSCR). One of the shRNA constructs (sh1) was
designed using the publicly available siRNA Target
Finder (Ambion, Austin, TX, USA), and three
constructs (sh2, sh3 and sh4) were designed as
described previously.
30 The forward sequences of
the shRNA contructs are as follows: sh1:
GGTTATTTCATACTTCGGT, sh2: TCGAAGAGCTGC
TGGATGA, sh3: TATGTACACTGACCATTAA and
sh4: GAACTACCCAATCGTATGT. In a 50 to 30 order
the shRNA constructs contained the following: a
19–nt sense sequence, a short spacer (ttcaagaga), a 19–
nt reverse sequence complementary to the sense
strand and five thymidines (RNA polymerase-3
transcriptional stop signal). These sequences were
annealed and cloned between Hind III and BamHI
restriction sites in the pSilencer 3.0–H1 vector
(Ambion), downstream to the H1-RNA polymerase-3
promoter.
BDNF cloning. Rat total DNA was extracted from a
C6 rat glioma cell line using the GenElute mammalian
genomic DNA purification kit (Sigma-Aldrich, St
Louis, MO, USA), and the coding sequence of the
BDNF gene was subsequently amplified by PCR using
an Expand High Fidelity DNA polymerase (Roche
Diagnostics, Penzberg, Germany). The following
primers were used: 50-ATTTGCGGCCGCTTCCACCAG
GTGAGAAGAGTG-30 (forward) and 50-TTTAG
GATCCTATCTTCCCCTTTTAATG-30 (reverse). NOT1
and BamH1 (Fermentas, Burlington, Canada)
restriction sites were introduced, which allowed for
the insertion of the BDNF sequence downstream to
the cytomegalovirus promoter in a pcDNA3.1(-)
expression vector (Invitrogen, Carlsbad, CA, USA).
Effectiveness of the various shRNA sequences in
vitro. 293T cells were cultured with Dulbecco’s
modified eagle’s medium (Gibco-BRL, Invitrogen,
Belgium) containing 10% fetal calf serum (GIBCO-
BRL). Twenty-four hours before transfection, 293T
cells were split 1:5 to reach 60% confluency. A
quantity of 8.4mg of either one or a mix of the shRNA
vectors (sh1-sh4 or shSCR), or a control plasmid
expressing green fluorescent protein (GFP) only, were
transfected with 10mg of BDNF expression vector into
the 293T cells using the calcium phosphate method.
Precipitates were formed by the addition of the
plasmids to TE buffer (1mM Tris, 0.1mM EDTA,
pH=8) supplemented with 250mM CaCl2 in a final
volume of 500ml. Then, 500mlo f2  HEPES-buffered
saline (281mM NaCl, 100mM HEPES, 1.5mM
Na2HPO4, pH=7.12) was added drop wise and the
solution was vortexed. The resulting precipitate of
each plasmid solution was immediately added to 293
T cell cultures. The cell media were replaced after 14
to 16h, and collected at 24, 48 and 72h post-
transfection. Secreted BDNF levels were measured
using DuoSet ELISA development system (R&D
systems, Minneapolis, MN, USA) as we described
earlier,
31 and then normalized per 10
6 cell number.
Cloning lentiviral silencing vectors. Complete H1
promoter and shBDNF, or shSCR cassettes were
amplified from pSilencer plasmid by PCR using
Expand High Fidelity DNA polymerase and the
following primers: 50-GCGCTCGAGGTTTTCCCAGT
CACGAC-30 (forward) and 50-ATCGAGTTAGCTCA
CTCATTAGGC-30 (reverse). The forward primer was
designed to include an XhoI restriction site. Next, the
PCR product was cloned into a transfer plasmid of the
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EcoR5 restriction sites located downstream to the
central polypurine tract (cPPT) of the transfer
plasmid. LVs were named LV-shBDNF and LV-
shSCR, respectively, and a LV expressing the GFP
only was named LV-GFP.
High titer lentiviral preparation. 293Tcells were split
into 15cm plates, precoated with 20mgml
 1 of Poly-L-
lysin (Sigma-Aldrich, USA), to reach 60% confluency.
Cells were transfected using polyethyleneimine as
described previously.
32 In brief, on the transfection
day, medium was replaced with Dulbecco’s modified
eagle’s medium (which did not include fetal calf
serum). DNA mixture containing 26mg of transfer
plasmid, 16.9mg of packaging plasmid (encoding viral
Gag and Pol proteins (pCMVDR8.91)), and 9.1mgo f
envelope plasmid (encoding the envelope of vesicular
stomatitis virus (pCI)) and 78ml of 1mgml
 1
polyethyleneimine in a total volume of 1.5ml
Dulbecco’s modified eagle’s medium was prepared.
The mixture was incubated for 10min at room
temperature and then added drop wise to plates
containing 293T cells. After 16h transfection, the
medium was replaced with Dulbecco’s modified
eagle’s medium supplemented with 10% fetal calf
serum. Forty eight and seventy two hours after
transfection, medium was collected, cleared by low
speed centrifugation, filtered through 0.45mm-pore-
size filter and ultracentrifuged at 25000r.p.m. for 2h
in 41C (Beckman Coulter BV, Mijdrecht, the
Netherlands) to obtain high titer viral stocks. The
pellet was resuspended in 0.1 M phosphate-buffered
saline (PBS), aliquoted, and stored at  801C until
further use. To determine titer of the viral stocks, 10
5
293T cells were infected with 5mlo r2 0 ml of viral
stock. After 48h, cells were fixed and then analyzed
with fluorescence-activated cell sorting and GFP-
positive cells were detected. LV stock titers were
expressed as transducing units (TU) per milliliter, and
ranged in the order of 10
9 TUml
 1.
Validation of LV-shBDNF activity in vitro. C6 rat
glioma cells were grown to 60% confluency and
infected with LV-shBDNF, LV-shSCR or LV-GFP
supplemented with polybrene (8mgml
 1). Cells were
allowed to grow to 100% confluency and medium
was replaced. Twenty-four hours later, medium was
collected and stored at  201C for further analysis,
and cells were harvested, rinsed twice with ice-cold
PBS, and lysed with RIPA buffer (140mM NaCl,
20mM Tris, pH=7.4, 10% glycerol, 1% Triton X-
100, 0.5% deoxycholate, 0.1% SDS, 2mM EDTA,
1m M phenylmethylsulfonyl fluoride and leupeptin at
20mgml
 1). Lysates were centrifuged at 14000r.p.m.
for 10min at 41C, the pellet was discarded, and
supernatant was aliquoted and stored at  201C for
further analysis. BDNF protein levels were
determined using DuoSet ELISA development
system (R&D systems). Results were normalized per
cell number for medium samples, or per total protein
concentration (Bradford assay, Bio-Rad, Hercules, CA,
USA) for protein extraction samples.
In vivo
Animals. Ten-week-old Sprague–Dawley male rats
were supplied by the Animal Breeding Center of the
Weizmann Institute of Science (Rehovot, Israel).
Animals were individually housed on a 12h light/
12h dark cycle (lights on at 0700h) with food and
water ad libitum. All animals were handled according
to the regulations formulated by the Institutional
Animal Care and Use Committee, which are in
complete accordance with the NIH guidelines for
care and use of laboratory animals.
Intracranial surgery. Rats were anesthetized with
ketamine (170mgkg
 1) and acepromazine
(1.7mgkg
 1) and placed in a stereotaxic frame.
Stainless steel guide cannulae (Plastics One, Roanoke,
VA, USA) were implanted bilaterally into either the
dorsal dentate gyrus (dDG) (n=61), CA3 (n=18) or
ventral subiculum (vSUB) (n=22) subregions of the
hippocampus using the coordinates described below
(relative to bregma and according to the atlas of Paxinos
and Watson, 1998).
33 dDG:  3.8 anteroposterior, þ2.4
mediolateral and  1.95 dorsoventral (from dura) at a
lateral angle of 101; CA3:  3.8 anteroposterior, 4.47
mediolateral and  1.36 dorsoventral (from dura) at a
lateral angle of 101;v S U B : 6.5 anteroposterior, þ7.05
mediolateral and  3.7 dorsoventral (from dura) at a
lateral angle of 161.
Microinjection of LV-shRNA. A week after surgery,
rats were evaluated for their sucrose preference levels
(see section ‘Sucrose preference test’ for description)
and divided into two groups with similar averaged
preference. Two microliters of either LV-shBDNF
(treatment) or LV-shSCR (control) were microinjected
bilaterally into the specific hippocampal subregions
over 4min using a dual channel MAB 40 microdialysis
pump (Microbiotech/SE AB, Stockholm, Sweden).
Injectors were left in place for 2min after completing
the injection to ensure adequate diffusion from the
injector tip. Microinjections were repeated three times
every other day. One week after the last injection, the
behavioral testing was initiated. All the behavioral
assessments described below were performed for each
rat, in the same order as written below.
Sucrose preference test. Sucrose preference was
performed as we have previously described.
31,34 Rats
had access to two drinking spouts positioned side-by-
side at the rear of the cage. Fluid consumption was
recorded by weighing the bottles every morning
between 0930 and 1000h. Sucrose solution
(prepared in tap water) was placed in one bottle and
tap water in the other. Rats were tested for 4 days,
followed by 1 day of only tap water and then bottle
positions were switched and rats were tested for an
additional 4 days to control for side preference.
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average percentage of sucrose consumption of the
total liquid consumption.
To increase the sensitivity of this method, different
concentrations of sucrose solution were measured in
order to examine which concentration of sucrose
could reliably be distinguished (Supplementary Fig-
ure 6). On the basis of dose–response curve, we chose
a high concentration (2%) at which rats strongly
preferred the sucrose solution, and a low concentra-
tion (0.2%) at which rats show a significant, but
moderate sucrose preference over plain water. We
have previously shown that this method has in-
creased sensitivity and allows for measurement of
more subtle, but significant reductions of sucrose
preference when applied to the chronic mild stress
model for depression.
31,34
Home-cage locomotion. Chronic monitoring of
locomotion was performed in the home cage using a
computerized Inframot system (TSE, Bad Homburg,
Germany) as described previously,
31,34 which is based
on infrared sensors located above the home cage of
each rat. Mobility during the dark period (over 12h
per night) was measured for 5 days. Increasing the
measurement time in untouched animals in their
home cages increases the stability and reproducibility
of locomotion data and therefore enhances the
probability of observing significant and replicable
behavioral changes.
Exploration and novelty-induced behavior. Loco-
motion was performed as we have previously
described.
31,34 Rats were placed in a 40 40cm
exploration box (ActiMot System Activity Chamber,
TSE). Then, distance traveled and number of rearings
were recorded automatically over 10min. The
distance traveled was estimated by beam breaks of
32 photo beam pairs, separated by 2.5cm and placed
3cm above the floor. The rearing activities of rats
were detected by the number of beam breaks of 16
photo beam pairs, separated by 2.5cm and placed
15cm above the floor. The exploration box was
thoroughly cleaned between tests.
Forced swim test. A modified FSTwas conducted in
a cylindrical tank (40cm high and 18cm in diameter;
constructed at the Weizmann Institute), as we have
previously described.
31,34,35 The water temperature
was kept at 241C( 2 1C above room temperature) and
the water level was such that the rat could not touch
the bottom with its hind paws. Rats were given a
single 10min exposure to the swim tank and were
videotaped. Video films of each FST session were
carefully analyzed by an observer blind to the
treatment groups, using our locally developed
software for a computer-attached joystick.
35 The
computerized analysis for FST was developed in our
laboratory to continuously follow the limbs of the
rats
35 and detect fine alterations in mobility
throughout the test. This allowed for a sensitive
analysis of more information than the standard
scoring protocols. In addition, immobility time was
measured manually.
Morris water maze. The Morris water maze was
performed as we described previously.
36 Briefly, rats
were trained and tested for 4 consecutive days and
tested again on the fifth day. In the training sessions,
rats were placed in a water tank (diameter of 1.4m)
with a hidden platform placed 1.5cm below the water
surface. Visual cues for enhanced orientation were
available in the testing room and the water tank. The
latency from placement of the rat in the water until it
found the platform was recorded. Rats were allowed
to remain on the platform for 15s, and were then
placed back in their home cages. On the fifth day, the
platform was removed, and the time spent in each
quarter of the water tank was recorded.
BDNF measurements, histology and neurogenesis.
Punches and BDNF ELISA: The enzyme-linked
immunosorbent assay (ELISA) was performed on a
different group of rats that did not undergo behavioral
tests, in order to verify the efficiency of BDNF
knockdown in vivo. Rats were divided into three
different groups microinjected with either LV-GFP,
LV-shSCR or LV-shBDNF to the dDG. One week after
LV infections, rats were decapitated and their brains
were extracted, immediately frozen in isopropanol
and stored at  801C. Bilateral tissue punches were
obtained from the coronal sections generated by a
manual cut within the cryostat environment (at
 201C) and according to a rat brain atlas (Paxinous
and Watson, 1998).
33 The coronal sections used for
punches of the dDG were taken from  2.3 to  4.3mm
from bregma. Protein extraction and sandwich ELISA
were performed as we previously described,
31 and
BDNF concentration was normalized per total protein
or per tissue weight. Similar results were obtained
when normalized in both ways, and results are
presented after normalization to total protein levels.
BrdU administration: Following the behavioral
tests, rats were injected intraperitoneally with
50mgkg
 1 bromodeoxyuridine (BrdU; Sigma-
Aldrich) at 12h intervals for 2 days. Twenty four
hours or a week after the last BrdU injection, rats were
deeply anesthetized and transcardially perfused
using PBS supplemented with 4Uml
 1 heparin
(Merck Biosciences, Darmstadt, Germany), followed
by fresh 2.5 % paraformaldehyde (J.T. Baker,
Deventer, Holland) supplemented with 5% sucrose
(J.T. Baker) in PBS. Brains were removed, postfixed
overnight, and allowed to sink in 2.5%
paraformaldehyde supplemented with 30% sucrose
in PBS solution. The coronal sections (30mm) were
collected using a cryostat (Leica CM 3050 S,
Nussloch, Germany) and placed into 24-well plates
containing 0.01% azide (Sigma-Aldrich) in PBS and
were stored at 41C until further use.
Knockdown of BDNF in specific brain sites
D Taliaz et al
83
Molecular PsychiatryImmunostaining: GFP detection: Free-floating
sections were mounted on SuperFrost Plus glass
slides (Menzel Glaeser, Braunschweig, Germany),
and GFP photomicrographs were acquired using a
Nikon E800 microscope (Tokyo, Japan) equipped with
filter for Cy-2 epifluorescence.
BDNF detection: After GFP photomicrographs were
acquired, slices were allowed to dehydrate, immersed
in citrate buffer (2.1gl
 1 citric acid monohydrate,
pH=6) and boiled for 15min in a microwave. Slices
were then cooled to room temperature for 30min and
washed. Sections were incubated for 1h with 20%
normal horse serum (Vector, Burlingame, CA, USA)
and 0.05% saponin (Sigma-Aldrich, USA). Sections
were then covered with anti-BDNF antibodies
(Alomone, Jerusalem, Israel) diluted 1:500 in PBS
containing 0.05% saponin and 2% normal horse
serum at room temperature. The following day, slices
were washed and incubated for 1h with 1:200 Cy-3-
conjugated donkey anti-rabbit secondary antibodies
(Jackson Immunoresearch, West Grove, PA, USA).
Sections were washed and were then covered with
Hoechst solution (1:2000, Sigma-Aldrich) for 30–60s
to mark the nuclei of the cells. As a control for
nonspecific staining, sections were incubated in
identical conditions, without the corresponding pri-
mary antibody.
BrdU and DCX: detection Brain sections were
incubated in 2 N HCl at 371C for 30min, followed by
10min incubation in 0.1 N boric acid. After washing,
sections were incubated for 1h with 20% normal
horse serum and 0.3% Triton X-100 and then for 12h
at room temperature with 0.3% Triton X-100, 2%
normal horse serum, rat anti-BrdU antibodies (1:200;
Oxford Biotechnology, Oxford, UK), and goat anti-
DCX (1:300; Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Sections were then washed and incubated
for 1h with Cy-2-conjugated donkey anti-goat and
Cy-3-conjugated donkey anti-rat (1:200; Jackson
ImmunoResearch) secondary antibodies.
Quantification
A Nikon E800 microscope was used for analysis.
Proliferation was assessed by bilateral counting of
BrdUþ cells in the subgranular zone of the dentate
gyrus (DG) (defined as the zone of the hilus, the width
of two cell bodies, along the base of the granular
layer). Neurogenesis was evaluated by counting the
cells that were double labeled with BrdU and
doublecortin X (DCX). For quantification, double-
labeled cells were counted in six coronal sections
(150mm apart) per infected brain region. All counts
were performed manually by an observer who was
blinded to the experimental groups. To obtain an
estimate of the total number of labeled cells per
infected region, the total number of cells counted in
the selected coronal sections from each brain was
multiplied by the volume index (the ratio between the
volume of the infected region and the total counted
sections). For quantification of the infection spread
in vivo, one in every six slices was collected from the
anterior to the posterior edge of the injections region
(until no GFP could be observed). The number of
brain slices expressing GFP was multiplied by 30mm
(thickness of each slice) and by 6 (number of skipped
slices). The medial-lateral and the dorsal-ventral
spread were evaluated based on the central coronal
section within the infected area. BDNF, GFP and
Hoechst immunoreactivity were quantified using
Image Pro Plus 4.5 software (Media Cybernetics,
Bethesda, MD, USA) by measuring the intensity per
unit surface area at the dDG, CA3 and vSUB. At least
six hippocampal sections per rat were used for this
analysis.
Statistical analysis
Results are expressed as mean±s.e.m. A two-tailed
unpaired Student’s t-test was used for analyses of the
behavioral experiments, except for the learning curve
of the Morris water maze test in which a two-way
repeated measures analysis of variance was per-
formed. One-way analysis of variance was used for
the BDNF analysis in vitro and in vivo, followed by
Fisher post hoc tests.
GenBank accession number
Brain-derived neurotrophic factor GenBank accession
number NM_012513.
Results
Induction of localized BDNF reduction
We designed four different sequences of shRNAs
complementary to the coding exon of the rat BDNF
gene, that is common to all isoforms of this gene,
28
and then tested which sequence most effectively
reduces BDNF levels in vitro (Supplementary
Figure 1). The most effective sequence was inserted
into a lentiviral vector (LV-shBDNF) tagged with GFP.
The LV-shBDNF was allowed to infect a C6 rat
glioma cell line, which naturally expresses the BDNF
protein. Forty-eight hours after infection, we observed
a 75% reduction in BDNF secretion. LV expressing
GFP and scrambled shRNA (LV-shSCR) or GFP only
(LV-GFP) caused no reduction in BDNF secretion
(Figure 1a). The measurements of BDNF protein
extracted from C6 cells revealed similar results
(Supplementary Figure 2). We then tested the ability
of the same LV-shBDNF constructs to induce knock-
down in vivo. Injection of the viral vectors into the DG
of rats resulted in localized infection as shown by
GFP expression (Figure 1d). The average radius of
infection was 1.14±0.08mm, and the viral infection
was restricted primarily to the DG as observed by cells
expressing GFP (Supplementary Figure 3). BDNF
levels within slices taken from the site of DG infection
were reduced by 69.37%±10.52 in rats injected with
the LV-shBDNF relative to that of control rats injected
with the LV-shSCR or the LV-GFP (Figure 1b). In
addition, in a different group of rats, BDNF levels
measured by ELISA on a tissue punch of the dDG
infected with LV-shBDNF were reduced by
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the LV-shBDNF was injected into the CA3 or the
vSUB, BDNF levels were reduced by 51.56%±1.78
and 52.48%±9.08, respectively. To verify that the
decreased expression of BDNF was not caused by the
damage of the tissue due to the viral injections, we
examined the injection site by nuclear Hoechst
staining. No change in cell density was observed
(Figure 1d).
Behavioral effects of BDNF knockdown in the dDG and
the CA3
To investigate the effect of BDNF knockdown in
specific brain sites on behavior, we used a battery of
behavioral assays measuring home-cage locomotion,
exploration of a novel environment, sucrose
preference and activity in FST. In addition, we
measured learning and memory in the Morris water
maze. Local injection of LV-shBDNF into the dDG
Figure 1 Validation of LV-shBDNF infection and brain-derived neurotrophic factor (BDNF) knockdown (KD) in vitro and
in vivo. BDNF protein expression was measured in a C6 rat glioma cell line and in vivo in response to infection with lentiviral
vector (LV) expressing either green fluorescent protein (GFP) only (LV-GFP; infection control), scrambled shRNA (LV-shSCR;
shRNA control) or shRNA complementary to the coding axon of the rat BDNF gene (LV-shBDNF; active sequence). Panel a
presents BDNF levels measured in a C6 cell medium 48h after infection and normalized per 10
6 cell number. Data are
presented as percentages of BDNF secreted from noninfected control cells. One-way analysis of variance (ANOVA) reveals a
significant main effect of treatment (F(3,20)=374.756, P<0.001). Differences between the various LV treatments were
assessed using Fisher post hoc analysis (***P<0.001; n=6 per treatment). Panel b presents BDNF levels in the dentate gyrus
(DG) measured by immunohistochemistry and epifluorescence microscopy. The intensity per unit area was measured for
each slice. BDNF levels are expressed as a percentage of control, by measuring the intensity in slices taken from infected rats
relative to control slices taken from the noninfected rats. One-way ANOVA revealed a significant main effect of treatment
(F(3,17)=29.926, P<0.01). Differences between control and infected brains were assessed using Fisher post hoc analysis
(**P<0.01; n=5 to 6 per group). Panel c presents BDNF levels in the dDG measured by ELISA and normalized per total
protein. BDNF levels are expressed as a percentage of control. One-way ANOVA revealed a significant main effect of
treatment (F(3,14)=5.868, P<0.01). Differences between control and infected brains were assessed using Fisher post hoc
analysis (**P<0.01; n=4 or 5 per group). Panel d presents representative micrographs of hippocampal slices including the
dDG from the rats injected with LV-shSCR (control) or LV-shBDNF (BDNF KD). The micrographs in the left present the
infection spread based on the GFP expression (green) within the sections. BDNF protein expression was visualized by
immunohistochemical staining (middle lane). Note the significant reduction in BDNF expression induced by the LV-shBDNF
microinjection. Cell nuclei were visualized using Hoechst staining (lower lane). The micrographs on the right show a higher
magnification of an infected hippocampal region. The upper lane shows GFP expression as an infection marker, whereas the
middle lane shows BDNF protein staining. The lower lane shows superimposition of the upper and middle lanes to highlight
cells expressing both GFP and BDNF. The arrows highlight that while the rat brain infected with LV-shSCR show BDNF
expression within infected (GFP) cells, none of the infected cells in the LV-shBDNF rat brain show BDNF expression. Scale
bar=200mm at the left micrographs and 20mm at the right micrographs.
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preference over plain water (Figure 2a). This was
evident when testing preference for low (0.2%) but
not high (2%) concentrations of sucrose solutions
(Supplementary Figure 4). In the FST, a significant
reduction in the total activity score (measured by a
computerized program
35) was induced by BDNF
knockdown in the dDG (Figure 2b). However, no
significant differences were observed when only the
immobility time was measured (Supplementary
Figure 5). In addition, home-cage locomotion, but
not exploration of a novel environment, was reduced
by the BDNF knockdown in the dDG (Figure 2c,d).
Finally, BDNF knockdown in the dDG induced a
delay in spatial learning as measured in the Morris
water maze (Figure 2e), but had no effect on
performance in a subsequent memory probe test
(Figure 2f).
Figure 2 Behavioral analysis of rats subjected to brain-derived neurotrophic factor (BDNF) knockdown (KD) in the dorsal
dentate gyrus (dDG). Lentiviral vector (LV)-shBDNF (knockdown) or LV-shSCR (control) constructs were injected into the
dDG of mature rats. The battery of behavioral tests was initiated 3 weeks after recovery from the surgery and the following
parameters were measured: sucrose preference (a), activity in a modified forced swim test (FST) (b), home-cage locomotion
(c), exploration of a novel environment (d), latency to reach the platform in the water maze task (e) and percent of time spent
at the target quadrant during the probe trial in the water maze task (f). Sucrose preference was assessed over a 10-day period
using a 0.2% sucrose solution (t(43)=3.526, P=0.01). A modified FSTwas videotaped, and activity was scored and analyzed
using our locally developed software which involves a computer attached joystick
35 (t(38)=2.183, P<0.05). Locomotion was
automatically measured over four consecutive nights in the home cage of rats (t(41)=2.855, P<0.01). The total distance
traveled and number of rearings were automatically quantified in the test for exploration in a novel environment. The water
maze task consisted of five training sessions over 5 days, and a test day 3 days later. A two-way repeated measures analysis of
variance (ANOVA) revealed a significant Group X session interaction (F(1,26)=4.835, P<0.05). In the water maze task, the
latency to find the platform was significantly lower in control rats than in BDNF KD rats at days 2, 3 and 4 (t(26)>2.115,
P<0.05) but not at days 1 and 5. The probe trial was conducted 3 days after the training sessions, and the percentage of time
spent at the target quadrant was measured during a 1-min test. The level of a random distribution between quadrants was
25%. Values are mean±s.e.m. (n=20 to 23 per group for all tests except for the water maze in which n=14 per group;
*P<0.05, **Pr0.01).
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several behavioral deficits, injection of LV-shBDNF
into the CA3 did not induce any behavioral altera-
tions as measured using the same battery of tests
(Figure 3).
Behavioral effects of BDNF knockdown in the vSUB
Brain-derived neurotrophic factor knockdown in the
vSUB reduced sucrose preference significantly as
compared with control animals when sucrose con-
centration was 0.2% (Figure 4a). However, this
reduction was not significant when rats were tested
using a 2% sucrose solution (Supplementary
Figure 4). Activity in FST or home-cage locomotion
was not affected by BDNF knockdown in the vSUB
(Figure 4b, c). Similarly, locomotor activity in a novel
environment during the exploration test was not
affected by BDNF knockdown in the vSUB
(Figure 4d). Finally, BDNF knockdown in the vSUB
had no effect on learning and memory, as measured in
the Morris water maze paradigm (Figure 4e, f).
BDNF knockdown in the dDG reduces neuronal
differentiation in vivo
We tested whether local BDNF knockdown can
actually reduce hippocampal neurogenesis in vivo.
LV-shBDNF- and LV-shSCR-treated rats were injected
with BrdU 24h or 1 week before euthanasia, and
neurogenesis was evaluated by immunohistochemis-
try. BDNF knockdown in the dDG did not affect
proliferation, as measured by the number of BrdU
stained cells in the DG (Figure 5a–c). However,
neuronal differentiation was decreased by 60%, as
measured by the number of cells double stained with
BrdU and DCX (Figure 5a, c). Conversely, BDNF
knockdown in either the CA3 or the vSUB did not
affect proliferation or differentiation in the DG
(Figure 5d, e).
Discussion
This study provides direct evidence that reduced
BDNF protein levels, in specific hippocampal sub-
regions, can reduce neurogenesis in vivo and affect
Figure 3 Behavioral analysis of rats subjected to brain-derived neurotrophic factor (BDNF) knockdown (KD) in the CA3.
Lentiviral vector (LV)-shBDNF (knockdown) or LV-shSCR (control) constructs were injected into the CA3 of mature rats. The
battery of behavioral tests was initiated 3 weeks after recovery from the surgery and the following parameters were measured:
sucrose preference (a), activity in a modified forced swim test (FST) (b), home-cage locomotion (c), exploration of a novel
environment (d), latency to reach the platform in the water maze task (e) and percent of time spent at the target quadrant
during the probe trial in the water maze task (f), as described in Figure 2. Values are mean±s.e.m. (n=8 per group).
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BDNF knockdown in the dDG, but not in the CA3 or
the vSUB, induced a reduction in neuronal differ-
entiation and several behavioral impairments includ-
ing reduced sucrose preference, locomotion and
activity in the swim test. From another perspective,
the behavioral effects of current antidepressant drugs
were shown to be dependent on BDNF
10 and
neurogenesis.
5
Given that the depressive behavior cannot be
characterized by a single symptom in humans or in
animals, we used a battery of behavioral tests
associated with some symptoms of depression, in-
cluding anhedonia, loss of interest and motivation, as
well as fatigue and loss of energy (DSM IV, 2000). We
also tested spatial memory, as BDNF has been
implicated in long-term potentiation,
37 and learning
and memory mechanisms.
38 Moreover, cognitive im-
pairment is common in depressive individuals (DSM
IV, 2000). The set of behavioral deficits induced after
BDNF reduction in the dDG (but not the other sites)
such as reduced sucrose preference, home-cage
locomotion and activity in the FST can be associated
with depressive-like symptoms. It is important to note
that exploration of a novel environment was not
affected in the same animals, indicating that the low
scores measured in both the swim test and the home-
cage locomotion tests were not due to motor impair-
ment. Finally, in the Morris water maze, although
acquisition was initially impaired, differences were
not maintained and no effect was observed in the
probe test for memory, suggesting that BDNF in this
subregion does not have a critical function in spatial
memory.
Importantly, the battery of behavioral tests used in
this study was specifically designed to detect subtle
Figure 4 The behavioral effect of brain-derived neurotrophic factor (BDNF) knockdown in the ventral subiculum (vSUB).
Lentiviral vector (LV)-shBDNF (knockdown) or LV-shSCR (control) constructs were injected into the vSUB of mature rats. The
battery of behavioral tests was initiated 3 weeks after recovery from the surgery and the following parameters were measured:
sucrose preference (a), activity in a modified forced swim test (FST) (b), home-cage locomotion (c), exploration of a novel
environment (d), latency to reach the platform in the water maze task (e) and percent of time spent at the target quadrant
during the probe trial in the water maze task (f), as described in Figure 2. Values are mean±s.e.m. (* P<0.05, n=11 per
group). A significant difference between the experimental groups was observed only in the sucrose preference test
(t(20)=2.418, P<0.05).
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test, we examined which concentration of sucrose
could reliably be distinguished (Supplementary
Figure 6). On the basis of the dose–response curve,
we chose a high concentration (2%) at which all rats
strongly preferred the sucrose solution, and a low
concentration (0.2%) at which control rats showed a
significant, but moderate sucrose preference over
plain water. In the chronic mild stress model for
anhedonia,
39 we have previously found that when
repeated ongoing measurements are used, the lower
sucrose concentration provides a more sensitive
distinction between control rats and those exposed
to the chronic mild stress procedure.
31,34 In this study,
when using the lower sucrose concentration we
observed that BDNF reduction within the dDG and
vSUB (but not the CA3) significantly impaired
sucrose preference. Another methodological consid-
eration is the use of a computerized analysis for FST
that was developed in our laboratory to continuously
follow the limbs of rats
35 and detect fine alterations in
mobility throughout the test. This allowed for
analysis of more information than the standard
scoring protocols. The computerized analysis re-
vealed a significant effect of BDNF knockdown in
the dDG (but not the vSUB or the CA3) on FST score.
We also attempted to optimize our assessment of
locomotion by measuring the home-cage locomotion
of rats over a period of four consecutive nights in
addition to the commonly used exploration test.
Increasing the measurement time in untouched
animals in their home cages increases stability and
reproducibility of locomotion data and therefore
enhances the probability of observing significant
and replicable behavioral changes. Home-cage loco-
motion of rats with BDNF knockdown in the dDG (but
not the CA3 or vSUB) was significantly lower than
that of controls. On the other hand, a standard
locomotion test in exploration boxes did not reveal
alterations induced by BDNF knockdown in any of
Figure 5 The effect of brain-derived neurotrophic factor
(BDNF) knockdown on hippocampal neurogenesis. Neuro-
genesis in the subgranular zone (SGZ) was measured 2
months after the induction of BDNF knockdown (KD) in the
dorsal dentate gyrus (dDG), CA3 or ventral subiculum
(vSUB) of mature rats. Rats were injected intraperitoneally
with 50mgkg
 1 bromodeoxyuridine (BrdU) at 12h intervals
for 2 days. Twenty-four hours or a week later rats were
deeply anesthetized and transcardially perfused. Immuno-
histochemistry was performed to detect neuronal dividing
cells by counting the cells that incorporated BrdU into their
genome, and express the immature neuronal marker
doublecortin X (DCX), as shown in the small micrographs.
Representative micrographs of the dDG from rats injected
with lentiviral vector (LV)-shSCR (Control) or LV-shBDNF
(BDNF KD) into their dDG are presented in panel a.
Proliferation was measured by counting BrdU-stained cells
(upper lane), immature neurons were visualized by DCX
(middle lane), and differentiation was measured by count-
ing double-labeled BrdU and DCX cells (lower lane). Scale
bar=200mm. Panel b shows a quantitative analysis of
proliferation comparing control and BDNF KD rats after
LV infections in the dDG. This panel presents data from rats
that were euthanized 24h after BrdU injections. Panels c,d
and e show a quantitative analysis of proliferation and
differentiation comparing control and BDNF KD rats after
LV infections in the dDG, CA3 or vSUB, respectively. These
rats were injected with BrdU a week before euthanasia. A
significant effect of BDNF KD was observed only in the dDG
group and only in the number of differentiated neuronal
cells (BrdU þ DCX) (t(11)=5.672, P<0.001), but not in total
proliferation (BrdU). Values are mean±s.e.m. (***
P<0.001, n=6–9 per group).
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of BDNF knockout was measured in floxed BDNF
mice, whose hippocampuses were injected with Cre
recombinase-expressing viruses.
10,40 In these experi-
ments, no differences were detected in sucrose
preference, locomotor activity and percent of immo-
bility in FST following BDNF knockout (but
BDNF knockout impaired the behavioral effects of
current antidepressant medications). In this
study, BDNF knockdown in specific hippocampal
subregions of rats showed similar results when
using comparable parameters of high sucrose con-
centration (2%), locomotor activity in a novel envir-
onment and immobility time in FST. However, when
testing the animals using a low sucrose concentration
(0.2%; on the basis of dose–response curve, Supple-
mentary Figure 6
31,34) continuous monitoring of
locomotion in the home cages of rats
31,34 and a
sensitive computerized analysis of FST
31,34,35 a sig-
nificant effect of BDNF knockdown in the dDG was
detected.
Given the suggested function of neurogenesis in
depressive-like behavior and the mechanism of action
of antidepressant drugs in animal models,
5–8 we also
measured the effect of localized BDNF knockdown on
neurogenesis. In vitro studies have already estab-
lished a strong association between BDNF and
neurogenesis. Specifically, an addition of BDNF to
central nervous system-derived neuronal precursors
was shown to influence differentiation but not
proliferation.
41,42 Moreover, it has previously been
reported that the infusion of BDNF into the hippo-
campus of adult mice increases neurogenesis
in vivo.
21 However, no distinction was made between
neuronal differentiation and proliferation. To clarify
whether BDNF is necessary for hippocampal neuro-
genesis, it is essential to induce a localized knock-
down of BDNF in vivo and measure both proliferation
and differentiation. Studies which investigated this
by generating heterozygous BDNF knockout (BDNF
þ/ ) mice reported conflicting results; whereas one
study reported that these animals exhibit decreases in
the basal levels of proliferation and survival of newly
generated neurons,
43 another study reported an
increase in the basal proliferation in such animals,
44
while another group reported no difference in neural
survival in these animals.
45 Given that BDNF is
reduced early in development in these mice, it is
unknown what potential compensatory mechanisms
can occur during neurodevelopment. Recently, a
specific knockout of the tropomyosin-related kinase B
(TrkB) receptor in hippocampal neural progenitor
cells was performed by crossing mice harboring the
TrkB flox alleles to transgenic mice expressing the Cre
recombinase under the human glial fibrillary acidic
protein promoter or the Synapsin 1 (Syn) promoter.
46
In this study, specific deletion of TrkB in neural
progenitor cells resulted in impaired proliferation and
neurogenesis. In contrast, deletion of TrkB in differ-
entiated neurons did not affect neurogenesis. Con-
flicting results were reported in a parallel study in
which knockout of the catalytically active site of the
TrkB receptor was performed specifically in the radial
glia-like stem cells of the mice DG.
47 In that study the
composition of progenitors and new neurons that exit
the cell cycle was not altered by deletion of TrkB.
However, the survival of newborn neurons was
shown to be critically dependent on the activation
of the TrkB receptor. The apparent contradiction
between these studies can be explained in several
ways; however, in order to study the function of the
BDNF protein itself in neurogenesis, a specific
knockdown of BDNF should be performed. Indeed,
TrkB is considered the high-affinity receptor for
BDNF,
48 however, it is also the high-affinity receptor
for neurotrophin 4 (NT4).
48 Although NT4 /  knock-
out mice do not show impaired neurogenesis,
45 this
might be attributed to compensatory mechanisms that
could develop because such transgenic mice do not
express NT4 from as early as their embryonic
development. Moreover, BDNF may have effects that
are not mediated by the TrkB receptor. Even though
primary neurospheres derived from the DG of adult
TrkB knockout mice and treated with BDNF displayed
reduction in both number and size relative to those
derived from the control mice,
46 the effect of BDNF on
neurogenesis in vivo was not measured in the TrkB
knockout mice. Here we report that BDNF reduction
in the dDG caused a significant reduction in neuro-
genesis. Specifically, BDNF was necessary for differ-
entiation but not the proliferation of newborn
neurons, as the only difference between BDNF knock-
down and controls was the number of cells expressing
both proliferation marker (BrdU) and immature
neuronal marker (DCX), whereas the total number of
proliferating cells, either 24h (Figure 5b) or 7 days
(Figure 5c) after BrdU injections, was unchanged.
Consistent with our findings, an in vitro study
showed that BDNF has a function in differentiation,
but not proliferation, of neuronal precursors.
41 In
contrast to the remarkable effects of BDNF knock-
down in the dDG on neuronal differentiation and
most behavioral measures, BDNF reduction in the
CA3 had no effect on neurogenesis or on any of the
tested behaviors, whereas BDNF reduction in the
vSUB affected sucrose preference (an indicator of
anhedonic behavior
49) only, but not any of the other
tested behaviors or neurogenesis. This suggests that
anhedonia is not necessarily an outcome of reduced
hippocampal neurogenesis.
Even though impairment of BDNF expression
within the CA3 did not affect any of the tested
behaviors, previous studies indicated that BDNF
mRNA levels within the CA3 were increased by the
antidepressant treatments.
1,50 It is important to con-
sider the hippocampal circuitry, especially when
interpreting our CA3 results. The mossy fibers of the
DG granule cells project to the pyramidal neurons of
the CA3 subregion
51 and an anterograde transport and
secretion of BDNF to the synapse has been reported.
38
Therefore, although injection of the LV-shBDNF into
the CA3 induced a significant reduction in local
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partially compensate for this loss.
Although alterations in BDNF levels in hippocam-
pal subregions, such as the DG
3,14 and the CA3,
1,50
have been associated with depressive behavior, the
function of subicular BDNF expression has not been
studied in this regard. We postulate that the vSUB has
a possible function in depressive behavior, as it
strongly influences the reward system by direct
projections to the nucleus accumbens
52 and by
excitatory input to dopamine (DA) neurons in the
ventral tegmental area that can induce DA release in
the nucleus accumbens.
53 In our study, knockdown of
BDNF in the rat vSUB caused a significant reduction
of sucrose preference, an indicator of anhedonic-like
behavior.
49 Previous studies have shown that a
sodium channel blocker injected into the vSUB
causes a near-complete blockage of novelty-induced
DA release of the mesolimbic DA pathway.
54 Further-
more, when a glutamate receptor antagonist is applied
to the nucleus accumbens, activation of DA neurons
by stimulation of the vSUB is blocked.
55 Comparably,
BDNF reduction within the vSUB may impair
glutamate secretion to the nucleus accumbens, as
in vitro studies indicate that BDNF can rapidly
potentiate glutamatergic transmission and release.
56
Therefore, BDNF reduction in the vSUB can cause
deficits in reward function and induce anhedonia. It
is interesting to note that a selective ablation of the
BDNF gene from the ventral tegmental area induced
antidepressant-like effect in the social defeat stress
paradigm,
57 whereas in this study, BDNF reduction in
the vSUB resulted in anhedonic-like behavior. In-
deed, different roles were suggested for BDNF in the
hippocampus and the ventral tegmental area, despite
the interaction between these systems.
58
In conclusion, this study strengthens the neuro-
trophic hypothesis of depression. Using LV and RNA
interference we showed that hippocampal BDNF
reduction affects several behaviors associated with
depression. We also defined the dDG as the hippo-
campal subregion most affected by this reduction, and
showed that BDNF reduction in the vSUB can induce
anhedonic-like behavior. Finally, we showed that
BDNF reduction impairs neuronal differentiation
(but not proliferation) in the hippocampus.
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